

Mediterranean Diet, Omega-3 Show Anti-AD Effect

BY ROBERT FINN
San Francisco Bureau

Adherence to a Mediterranean diet is associated with reduced risk for Alzheimer's disease, and supplementation with omega-3 fatty acids appears to slow the progression of mild forms of the disease, according to two separate studies appearing in *Archives of Neurology*.

In a case-control study involving 1,984 people (average age 76.3 years), a greater

degree of adherence to the Mediterranean diet was associated with a significantly lower risk of Alzheimer's disease, according to the article, which appeared online on Oct. 9, 2006. The investigators, led by Dr. Nikolaos Scarmeas of Columbia University in New York, assessed adherence to the Mediterranean diet on a 9-point scale (*Arch. Neurol.* 2006 [Epub doi10.1001/archneur.63.12.noc60109]).

Participants were questioned extensively about their diets over the previous year,

and points could be accumulated for eating more than the median amount of fish, vegetables, legumes, and cereals; for eating less than the median amount of dairy, meat, and fat; and for drinking a moderate amount of alcohol.

Compared with people whose diets scored in the lower third of similarity to the Mediterranean diet, those with diets in the upper third were 69% less likely to have Alzheimer's. These results were adjusted for many factors, including age, sex, eth-

nicity, education, apolipoprotein E genotype, caloric intake, smoking, body mass index, and history of stroke, diabetes, hypertension, heart disease, and lipid levels.

The investigators found it noteworthy that their inclusion of a long list of vascular variables did not change the risk analysis. This finding indicates that the effect of the Mediterranean diet on Alzheimer's disease risk may be mediated by nonvascular mechanisms such as oxidation or inflammation. Indeed, other

Glycemic Control May Stop Dementia

MADRID — Tight control of blood glucose levels may decrease the incidence of dementia and Alzheimer's disease among patients with diabetes, researchers reported at the 10th International Conference on Alzheimer's Disease and Related Disorders.

The findings speak volumes about the need for early implementation of significant lifestyle changes among those at risk for diabetes, especially in light of the ongoing obesity epidemic, said Dr. Ronald Petersen, who moderated a press conference on the studies. "The number of people with Alzheimer's, and the number who will soon get it, is rising dramatically as the baby boomers turn 50, approaching the age of highest risk," said Dr. Petersen, vice chair of the Alzheimer's Association's Medical and Scientific Advisory Council. "Will this growth be redoubled by the rising tide of obesity and diabetes?"

Glycemic control is crucial in protecting diabetic patients from dementia, said Rachel Whitmer, Ph.D., of Kaiser Permanente, Oakland, Calif. Her population-based study included 22,852 members of Kaiser's Northern California Diabetes Registry surveyed from 1994 to 1996. Their mean age at baseline was 66 years; 66% were white, 10% black, and the rest were Hispanic, Asian, or Native American.

The patients were followed until 2005. By then, 11% had developed new-onset dementias. Hemoglobin A_{1c} (HbA_{1c}) was significantly associated with the incidence of dementia. Patients with the highest HbA_{1c} (15% and higher) were the most likely to develop dementia, with an elevated risk of 78% compared with those whose levels were below 10%. Diabetic patients are advised to keep their HbA_{1c} below 7%.

Those with HbA_{1c} levels of 12%-15% were 22% more likely to develop dementia, while those whose levels were between 10% and 11.9% had a 16% increased risk. The increased risks remained significant even after adjusting for age, race, gender, weight, and diabetes treatment.

"This shows us that tight glycemic control continues to be as important as patients' age," Dr. Whitmer said at the meeting, presented by the Alzheimer's Association. "And it will become more and more important as we experience the epidemic of obesity in the United States."

—Michele G. Sullivan

FIRST
IN A NOVEL
CLASS OF
SLEEP
AGENTS



Zolpidem is indicated for the treatment of insomnia characterized by difficulty with sleep onset. Zolpidem can be prescribed for long-term use. Zolpidem should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression. Zolpidem has not been studied in patients with severe sleep apnea, severe COPD, or in children or adolescents. The effects in these populations are unknown. Avoid taking Zolpidem with alcohol. Zolpidem has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms possibly associated with such changes in these hormone levels. Zolpidem should not be taken with or immediately after a high-fat meal. Zolpidem should be taken within 30 minutes before going to bed and activities confined to preparing for bed. The most common adverse events seen with Zolpidem that had at least a 2% incidence difference from placebo were somnolence, dizziness, and fatigue.

Please see adjacent Brief Summary of Prescribing Information.